ProteoPrinceps, LLC

Boulder, CO · Biotech

Gene expression manipulation therapeutics using the Sachi platform to reverse radiation-induced immune dysregulation and neurodegeneration in deep-space missions

proteovations.com →
Grants
$800K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Aeronautics and Space Administration · Phase II · Reversing Immune Dysregulation During Spaceflight Missions$799,992
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2129ProMIS Neurosciences Inc.—$39M
2130CASI Pharmaceuticals, Inc.—$35M
2131BLUE THERAPEUTICS, INC.——
2132ProteoPrinceps, LLC——
2133Rebiotix Inc.—$29M
2134Mahzi Therapeutics Inc.—$27M
2135INVIVO THERAPEUTICS HOLDINGS CORP.—$9.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.